Taipei Time, September 17, 2020 Polaris Group announced today that the first patient has been dosed in its Phase 1b trial of ADI-PEG 20 combined with radiotherapy and temozolomide for newly diagnosed glioblastoma multiforme (GBM).
The principal investigator is Dr. Wei from Linkou Chang Gung Memorial Hospital. This Phase 1b trial will enroll 26 patients.